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of 14 cases and a review of the literature
Hiromichi Suzuki1,2*, Daisuke Shichi3, Yasuharu Tokuda4, Hiroichi Ishikawa5, Tetsuhiro Maeno2
and Hidenori Nakamura6Abstract
Background: Pneumococcal vertebral osteomyelitis (PVO) is a rare disease whose clinical characteristics have not
been clarified. This study aimed to investigate the clinical features and outcomes of patients with PVO.
Methods: We retrospectively evaluated all adult patients diagnosed with PVO at three teaching hospitals in Japan
from January 2003 to December 2011. All cases were identified through a review of the medical records of patients
with invasive pneumococcal disease (IPD).
Results: Among 208 patients with IPD, we identified 14 with PVO (6.4%; 95% CI, 3.5–10%). All 14 patients (nine
male, five female; median age 69 years) had acquired PVO outside the hospital and had no recent history of an
invasive procedure or back injury. Five patients (36%) had diabetes mellitus, and four (29%) had heavy alcohol
intake. Fever (n = 13; 93%) or back pain/neck pain (n = 12; 86%) were present in most patients. The lumbar spine
was affected in nine patients (64%) but the cervical spine was the site of infection in four patients (29%). All
patients except one had a positive blood culture for Streptococcus pneumoniae, and there were no distant infected
sites in most patients (n = 10; 71%). Intravenous beta-lactam therapy was initiated within 1 week after the onset of
symptoms in 11 patients (79%). No patients died within 30 days, but one patient died from aspiration pneumonia
on day 37 after admission.
Conclusions: PVO was relatively common among adult patients with IPD, and mortality was low in this study.
S. pneumoniae may be the causative pathogen of vertebral osteomyelitis, especially among community-onset cases
without a history of invasive procedures or back injury.
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Vertebral osteomyelitisBackground
Streptococcus pneumoniae is an important pathogen that is
the main cause of community-acquired pneumonia [1], me-
ningitis [2], sinusitis [3] and otitis media [4]. S. pneumoniae
was also the third most common pathogen in bacterial
arthritis, identified in 6% of cases [5].
Pneumococcal vertebral osteomyelitis (PVO) is a very
rare disease, and the incidence has not been described in* Correspondence: hsuzuki@tmch.or.jp
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reproduction in any medium, provided the orprevious vertebral osteomyelitis studies [6-8]. In a litera-
ture review of 28 cases with pneumococcal spinal infec-
tions, Turner et al. [9] reported that most of the patients
had symptoms for weeks before diagnosis and that the
lumbar spine was the most common site of infection.
Severe complications were relatively frequent (endocar-
ditis 4/28, 14%; meningitis 5/28, 18%), and mortality was
high (7/28, 25%) [9]. However, these epidemiological
data were derived from case reports, which included
cases published more than 50 years ago. Currently, there
are few clinical studies of PVO available because of the
rare incidence of the infection.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2334/13/525In this study, we set out to determine the clinical epi-
demiology of patients with PVO in a 9-year retrospective
review of cases of invasive pneumococcal disease (IPD)
at three teaching hospitals with tertiary emergency med-
ical centers in Japan.
Methods
Patients
All adult patients with IPD who were admitted to Seirei
Mikatahara General Hospital (SMGH, 934 beds), Seirei
Hamamatsu General Hospital (SHGH, 744 beds), and
Tsukuba Medical Center Hospital (TMCH, 409 beds) from
January 2003 to December 2011 were retrospectively
reviewed. Patients with IPD were identified from a review
of the microbiological records of S. pneumoniae detection
in samples of blood, cerebrospinal fluid, joint fluid, or pus
from the abscess obtained by aseptic techniques. The ex-
clusion criteria were: (1) age ≤17 years; (2) a previous his-
tory of IPD; (3) concurrent detection of other pathogenic
bacteria from aseptic sites; and (4) patient refusal, as writ-
ten in the medical chart, to provide personal information
for out-of-care purposes. PVO was identified if the blood
culture or the pus aspirated from the intervertebral disk
space, or paravertebral, epidural or psoas abscesses was
positive for S. pneumonia. Vertebral osteomyelitis was con-
firmed by magnetic resonance imaging (MRI) or equivalent
imaging methods in the radiologist’s official report [10].
Data collection
Medical records, nursing databases, and microbiological
records from each hospital were reviewed by physicians
qualified as Fellows of the Japanese Society of Internal
Medicine, and all decisions were based on consensus.
The demographic and background data extracted from
patient records included the following: age; sex; body
weight; area of residence; functional capacity according to
activities of daily living (ADL) before onset of pneumococ-
cal bacteremia (Katz index [11]); comorbidities and the
Charlson comorbidity index [12]; use of immunosuppres-
sants or chemotherapy; administration of antimicrobial
agents before obtaining samples for blood culture; extent of
tobacco and alcohol intake; seasonality; presence of fever,
neck or back pain; time from onset of symptoms until
treatment; and preceding history of trauma, skin infections
or respiratory symptoms. Patients receiving immunosup-
pressants were defined as those receiving more than 1 mg
of prednisolone on a daily basis or any other immunosup-
pressive agent such as azathioprine or methotrexate. Pa-
tients with heavy alcohol intake were defined as those who
consumed more than 80 g of ethanol daily. The duration of
alcohol intake was not considered in this study.
Clinical and laboratory data included clinical severity,
antimicrobial susceptibilities determined by broth micro-
dilution methods, location of infection sites, complicationsand other sites of infection, initial antimicrobial agents
used, total duration of antibiotic therapy, invasive proce-
dures performed, morbidity and mortality. Clinical severity
was classified into sepsis and septic shock based on re-
cently described criteria [13]. Urine output and lactic acid
concentrations were not evaluated as criteria for severe
sepsis. The prothrombin time international normalized ra-
tio (PT-INR) was considered to be ≤1.5 in cases in which
prothrombin time was not determined. Other infective
sites including meningitis and infective endocarditis were
evaluated based on guidelines or established criteria
[14,15]. Pneumonia was considered to be present if a blood
culture was positive for S. pneumoniae and a chest X-ray
or computed tomography showed infiltration consistent
with pneumonia in the lung field. Other infective sources
such as septic arthritis, liver abscess, or retropharyngeal ab-
scess were considered to be other sites of infections when
contrast-enhanced computed tomography or MRI showed
compatible findings in an official radiologist’s report.
Outcomes were assessed by morbidity and mortality.
Morbidity was defined by the presence of any disorder
reducing ADL capacity (Katz Index) at discharge com-
pared with ADL before admission. Mortality was evalu-
ated at 14 and 30 days.
Statistical analysis
We compared the clinical characteristics of patients with
PVO with those of patients with other IPD. Categorical
variables were analyzed by the χ2 test or Fisher’s exact
test as appropriate. Continuous variables were compared
using the Student t test. The SPSS software package
(version 20, IBM, Armonk, NY, USA) was used for all
analyses. Statistical significance was defined as a two-
tailed p value <0.05. For the detection rate of PVO
among IPD, we computed exact confidence intervals for
a proportion from the binomial distributions.
Ethical considerations
This study was approved by the ethics committees of
Seirei Mikatahara General Hospital, Seirei Hamamatsu
General Hospital and Tsukuba Medical Center Hospital.
Results
We identified 219 adult IPD patients during the study
period, of whom 11 met the exclusion criteria (seven de-
clined non-medical use of personal information, three
had concurrent detection of other pathogenic bacteria,
and one was a recurrent case). Therefore, data from 208
cases were reviewed for infective sources. This resulted
in identification of 14 patients (6.4%; 95% CI, 3.5–10%)
with PVO, followed by 129 with pneumonia or empy-
ema, 25 with primary bacteremia, 23 with meningitis,
seven with joint infections and 10 with other infections.
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The characteristics and demographic data of the 14 pa-
tients with PVO are summarized in Table 1. The median
age was 69 years (range, 35–88 years) and five (36%) were
women. Compared with patients with other IPDs, heavy
alcohol intake was significantly more prevalent in patients
with PVO (29% vs. 6%, P = 0.02). Diabetes mellitus was
also common among patients with PVO (36%), although
its prevalence was not significantly greater than that in
IPD cases (19%). No patient was infected with HIV, or
had a history of skin infections, invasive procedures or
trauma. Only one patient had respiratory symptoms com-
plicated by pneumonia and no patient presented with in-
fluenza. While cases of other IPDs were relatively
frequent during the winter season (between December
and March), this trend was not seen in the PVO group
(50% vs. 14% for winter occurrences, P = 0.01).Table 1 Demographic data for cases of pneumococcal vertebr
pneumococcal disease
Pneumococcal vertebral os
n = 14 (*)
Age (y) (median) 69 (35–88)
Female 5 (35.7%)
Body weight (kg) (median) 52.8 (27.5–80.0)
ADL impairment (Katz Index) 0
Residents in long-term care facilities 0
Charlson comorbidity index (median) 1 (0–6)
Diabetes mellitus 5 (35.7%)
Malignancy 2 (14.3%)
Dialysis 0
Splenectomy 0
Immunosuppressants or chemotherapy 2 (14.3%)
Antibiotics used before culture obtained 1 (7.1%)
Smoking 6/12 (50.0%)
Heavy alcohol intake 4 (28.6%)
Seasonality (winter: December-March) 2 (14.3%)
Hospital-onset infections 0
Clinical Severity Scale
Severe sepsis 7 (50.0%)
Septic shock 0
Initial antimicrobial therapy
Beta-lactam agents monotherapy 7 (50.0%)
Beta-lactam agents combination therapy 7 (50.0%)
Other antibiotics 0
Duration of antibiotic therapy (days) 52 (20–330)
14-day mortality 0/14 (0%)
30-day mortality 0/14 (0%)a
ADL: activities of daily living.
(a) One patient died of aspiration pneumonia during hospitalization on day 37.Regarding clinical symptoms, fever was noted in 13
patients (93%) and a history of neck or back pain was
noted in 12 patients (86%). Two patients without neck
or back pain were identified as possible PVO cases by
computed tomography before systemic investigation of
pneumococcal bacteremia, and the diagnosis was later
confirmed by MRI. Most patients (11/14; 79%) received
effective antimicrobial therapy within 7 days after onset
of suspected symptoms. Only one patient was diagnosed
at 1 month after onset, and this patient subsequently de-
veloped endocarditis and required an operation.
All patients were hospitalized for treatment and seven
patients (50%) presented with severe sepsis, but no pa-
tient developed septic shock (Table 1). Drug susceptibil-
ity to penicillin G (minimum inhibitory concentration
(MIC) ≤ 2 μg/mL) and levofloxacin (MIC ≤ 2 μg/mL) was
preserved in all strains.al osteomyelitis and comparison with other invasive
teomyelitis Other invasive pneumococcal disease P-value
n = 194 (**) (*) vs (**)
73 (28–95) 0.433
70 (36.1%) 0.999
49.8 (29.5–92.4) 0.272
24/179 (13.4%) 0.325
15 (7.7%) 0.605
1 (0–9) 0.461
37 (19.1%) 0.164
35 (18.0%) 0.999
5 (2.6%) 0.999
3 (1.5%) 0.999
29 (14.9%) 0.999
28 (14.4%) 0.698
98/181 (54.1%) 0.780
12 (6.2%) 0.015
97 (50.0%) 0.011
22 (11.3%) 0.371
0.224
69 (35.6%)
31 (16.0%)
0.292
129/189 (68.3%)
51/189 (27.0%)
9/189 (4.7%)
15 (0–105) 0.035
29/188 (15.4%) 0.228
37/182 (20.3%) 0.076
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monly infected site and half of the patients with PVO
had an epidural abscess detected by MRI (Table 2). Two
patients had other joint infections and one patient had
an infection in the sternum. Other sources of infection
(each n = 1) were infective endocarditis, liver abscess and
pneumonia, retropharyngeal abscess, and meningitis.
The diagnosis of most patients (n = 13) was based on the
presence of pneumococcal infection by blood cultures,
while the diagnosis of one patient was based on the cul-
ture of pus obtained from the iliopsoas abscess.
All patients were treated with β-lactam therapy. Two
patients (14%) underwent invasive procedures, including a
patient with infective endocarditis who was referred to an-
other acute care hospital for surgery and survived. While
20% (37/182) of patients with other IPDs died within
30 days, none of the patients with PVO died within
30 days. In the patients with PVO, one patient died of as-
piration pneumonia on day 37 after admission and three
of the survivors (23%) had morbidity at discharge.
Discussion
We evaluated 14 cases of PVO, which is currently the lar-
gest number of patients analyzed in a study of PVO.
While diabetes mellitus and heavy alcohol intake were
common among patients with PVO, there were no pa-
tients with nosocomial S. pneumoniae infections, preced-
ing invasive procedures or injuries. Fever with back pain
or neck pain was present in most patients and the lumbar
spine was the most frequently affected site of pneumococ-
cal infections. Initial treatments were administered inTable 2 Infective sites and complications of
pneumococcal vertebral osteomyelitis
n = 14 (%)
Sites of involvementa
Cervical 4 29%
Thoracic 1 7%
Lumbar 9 64%
Sacral 3 21%
Complications
Epidural abscess + Iliopsoas abscess 5 36%
Epidural abscess 2 14%
Iliopsoas abscess 3 21%
Infective sites other than vertebral osteomyelitis
Arthritisb 2 14%
Othersc 4 29%
aThree patients had multifocal infection sites.
bOne patient had arthritis of the left shoulder joint and one had arthritis of the
left sacroiliac joint.
cOther sites of infection (each n = 1) included infective endocarditis, liver
abscess and pneumonia, retropharyngeal abscess, sinusitis, and meningitis.
One patient had both pneumonia and liver abscess along with
vertebral osteomyelitis.most patients within a week after onset of symptoms and
only one patient died during hospitalization.
We summarized adult PVO cases previously published
in the last 30 years (n = 26) [9,16-33] in Additional file 1:
Table S1. Compared with the previous 26 cases of PVO,
the clinical outcome was favorable in our current cases.
The better prognosis might have been derived from earlier
diagnosis of PVO and an adequate period of antimicrobial
treatment in our current cases. The initiation of treatment
seemed delayed for weeks after the onset of back pain in
previous cases. However it may also be a result of other
factors, such as the serotype, and the invasiveness of S.
pneumoniae. In our current cases and the previous 26
cases, diabetes mellitus and heavy alcohol intake were
common comorbidities and most cases also had a history
of fever, back pain or neck pain. The lumbar spine was
the most frequently affected site and the characteristics
were consistent with bacterial vertebral osteomyelitis
caused by other pathogens, mainly Staphylococcus aureus
[6-8,34,35]. Meanwhile, there were some differences in
PVO from other vertebral osteomyelitis. First, most of the
pneumococcal infections occurred outside hospital in
both our study and the previous 26 cases; nosocomial ac-
quisition, preceding operative procedures, skin infections
and back injury were rarely described. In addition, preced-
ing or concurrent infections of pneumococcal meningitis
were reported in one patient (7%) in our study and in
seven patients (27%) from previous cases reports.
In most previous studies of pneumococcal bacteremia
or IPD, the incidence of PVO was not described [36-39].
In a few other studies, the incidence was described as
0.2–1.3% [40-42]. Meanwhile, Turner et al. suggested the
possible underestimation of pneumococcal spinal infec-
tions in a report of eight cases over 13 years of experience
at a single university in the United Kingdom [9]. This sug-
gestion is supported by our results. Our study indicates
that we should be vigilant for a history of neck or back
pain in cases of pneumococcal bacteremia or other
pneumococcal infections. Blood cultures should be ob-
tained for patients with fever and also neck or back pain.
The possibility of concurrent PVO should be considered
in cases of pneumococcal meningitis so that patients re-
ceive an appropriate length of antimicrobial treatment. S.
pneumoniae may be the causative pathogen in vertebral
osteomyelitis, especially among community-onset cases
with no history of invasive procedures or back injury.
There are several limitations to this study. It was retro-
spectively conducted at three teaching hospitals in two re-
gions of Japan. The serotypes of S. pneumoniae were not
evaluated and the pneumococcal vaccination status was
not recorded or described in most patients and thus our re-
sults might not be the same as those for PVO in other re-
gions. Finally, the investigations for vertebral osteomyelitis
were not performed for all patients with IPD and patients
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ation. Thus actual incidence and mortality of PVO might
have been higher than that reported here. Larger clinical
studies are required, especially to determine risk factors
and to formulate appropriate prevention and treatment
strategies for PVO.
Conclusions
Our study suggests that vertebral osteomyelitis may be a
relatively common infective site among adult patients
with IPD. The mortality in those with PVO could be low
with early diagnosis and appropriate management. S.
pneumoniae should be considered as the important
causative pathogen in vertebral osteomyelitis, especially
among community-onset cases without a history of inva-
sive procedures or back injury.
Additional file
Additional file 1: Table S1. Summary of previously reported adult
pneumococcal vertebral osteomyelitis cases (1986–2012).
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